On March 5, 2024, Panbela Therapeutics, Inc. received a notification from The Nasdaq Stock Market LLC indicating that the company's common stock will be delisted due to non-compliance with the minimum stockholders equity requirement of $2.5 million as stipulated in Listing Rule 5550(b)(1). The delisting process will commence with the suspension of trading on Nasdaq at the opening of the market on March 7, 2024, followed by the filing of a Form 25 Notification of Delisting with the SEC after the appeal period has passed. Panbela Therapeutics expects its common stock to be quoted on the OTC Pink Market under the same symbol 'PBLA' during the interim. The company has the option to request a review of the Panel's decision within 15 days or the Nasdaq Listing and Hearing Review Council may opt to review the decision within 45 calendar days. Panbela Therapeutics plans to continue its SEC filings and periodic reports despite the delisting.

On March 5, 2024, Panbela Therapeutics, Inc. received a notification from The Nasdaq Stock Market LLC indicating that the company's common stock will be delisted due to non-compliance with the minimum stockholders equity requirement of $2.5 million as stipulated in Listing Rule 5550(b)(1). The delisting process will commence with the suspension of trading on Nasdaq at the opening of the market on March 7, 2024, followed by the filing of a Form 25 Notification of Delisting with the SEC after the appeal period has passed. Panbela Therapeutics expects its common stock to be quoted on the OTC Pink Market under the same symbol 'PBLA' during the interim. The company has the option to request a review of the Panel's decision within 15 days or the Nasdaq Listing and Hearing Review Council may opt to review the decision within 45 calendar days. Panbela Therapeutics plans to continue its SEC filings and periodic reports despite the delisting.